drugset / Trial / NCT00664521

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)

NCT00664521

Phase 2 Completed 27 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of combined treatment with atacicept and rituximab in subjects with active rheumatoid arthritis (RA) receiving re-treatment with rituximab.

Timeline

Start
2008-03
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Atacicept Protein / enzyme biologic 150 mg Subcutaneous
Background Rituximab Monoclonal antibody 1000 mg Intravenous

Indications